| Patterns of metastatic spread and tumor burden in unselected cancer patients using PET imaging: implications for the oligometastatic spectrum theory
Christ, S. M., Pohl, K., Willmann, J., Heesen, P., Heusel, A., Ahmadsei, M., … Guckenberger, M. (2024). Patterns of metastatic spread and tumor burden in unselected cancer patients using PET imaging: implications for the oligometastatic spectrum theory. Clinical and Translational Radiation Oncology, 45, 100724 (6 pp.). https://doi.org/10.1016/j.ctro.2024.100724 |
| First phantom-based quantitative assessment of scandium-44 using a commercial PET device
Lima, T. V. M., Gnesin, S., Nitzsche, E., Ortega, P. G., Müller, C., & van der Meulen, N. P. (2020). First phantom-based quantitative assessment of scandium-44 using a commercial PET device. Frontiers in Physics, 8, 241 (10 pp.). https://doi.org/10.3389/fphy.2020.00241 |
| Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute
Müller, C., De Prado Leal, M., Dominietto, M. D., Umbricht, C. A., Safai, S., Perrin, R. L., … Lomax, A. J. (2019). Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute. Pharmaceutics, 11(9), 450 (13 pp.). https://doi.org/10.3390/pharmaceutics11090450 |
| New <sup>55</sup>Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging
Radford, L. L., Fernandez, S., Beacham, R., Sayed, R. E., Farkas, R., Benešová, M., … Lapi, S. E. (2019). New 55Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging. Pharmaceuticals, 12(4), 166 (12 pp.). https://doi.org/10.3390/ph12040166 |
| Automated cGMP-compliant radiosynthesis of [<sup>18</sup>F]-(<em>E</em>)-PSS232 for brain PET imaging of metabotropic glutamate receptor subtype 5
Park, J. Y., Son, J., Yun, M., Ametamey, S. M., & Chun, J. H. (2018). Automated cGMP-compliant radiosynthesis of [18F]-(E)-PSS232 for brain PET imaging of metabotropic glutamate receptor subtype 5. Journal of Labelled Compounds and Radiopharmaceuticals, 61(1), 30-37. https://doi.org/10.1002/jlcr.3566 |
| Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor
Spinelli, F., Mu, L., & Ametamey, S. M. (2018). Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 61(3), 299-308. https://doi.org/10.1002/jlcr.3579 |
| Design and preclinical evaluation of an albumin-binding PSMA ligand for <sup>64</sup>Cu-based PET imaging
Umbricht, C. A., Benešová, M., Hasler, R., Schibli, R., van der Meulen, N. P., & Müller, C. (2018). Design and preclinical evaluation of an albumin-binding PSMA ligand for 64Cu-based PET imaging. Molecular Pharmaceutics, 15(12), 5556-5564. https://doi.org/10.1021/acs.molpharmaceut.8b00712 |
| Evaluation of the first <sup>44</sup>Sc-labeled Affibody molecule for imaging of HER2-expressing tumors
Honarvar, H., Müller, C., Cohrs, S., Haller, S., Westerlund, K., Eriksson Karlström, A., … Tolmachev, V. (2017). Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors. Nuclear Medicine and Biology, 45, 15-21. https://doi.org/10.1016/j.nucmedbio.2016.10.004 |
| Synthesis and biological evaluation of quinoxaline derivatives for PET imaging of the NMDA receptor
Milicevic Sephton, S., Vetterli, P. T., Pedani, V., Cermak, S., Chiotellis, A., Roscales, S., … Ametamey, S. M. (2017). Synthesis and biological evaluation of quinoxaline derivatives for PET imaging of the NMDA receptor. Helvetica Chimica Acta, 100(12), e1700204 (17 pp.). https://doi.org/10.1002/hlca.201700204 |
| <sup>44</sup>Sc-PSMA-617 for radiotheragnostics in tandem with <sup>177</sup>Lu-PSMA-617—preclinical investigations in comparison with <sup>68</sup>Ga-PSMA-11 and <sup>68</sup>Ga-PSMA-617
Umbricht, C. A., Benešová, M., Schmid, R. M., Türler, A., Schibli, R., van der Meulen, N. P., & Müller, C. (2017). 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Research, 7(1), 9 (10 pp.). https://doi.org/10.1186/s13550-017-0257-4 |
| Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
Müller, C., Vermeulen, C., Köster, U., Johnston, K., Türler, A., Schibli, R., & van der Meulen, N. P. (2016). Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharmacy and Chemistry, 1(1), 5 (5 pp.). https://doi.org/10.1186/s41181-016-0008-2 |
| Targeting of renal carcinoma with <sup>67/64</sup>Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging
Zimmermann, K., Grünberg, J., Honer, M., Ametamey, S., Schubiger, P. A., & Novak-Hofer, I. (2003). Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nuclear Medicine and Biology, 30(4), 417-427. https://doi.org/10.1016/S0969-8051(03)00019-2 |
